23-07-2019
panuwach / Shutterstock.com
Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office (USPTO) to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley (UC Berkeley).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Sigma-Aldrich, Merck KGaA, USPTO, CRISPR, Broad Institute, UC Berkeley, MIT, Harvard, Cas9, patent, genome editing
Merck KGaA secures CRISPR patents in Japan and Singapore
27-11-2019
Merck and Evotec strike CRISPR licensing deal
14-11-2019
Broad hits out at UC Berkeley in latest CRISPR battle
02-08-2019
USPTO revives fight over CRISPR patents
27-06-2019
Federal Circuit sides with Broad Institute in CRISPR clash
11-09-2018
